Lung cancer screening guide
Early Lung Cancer Detection: Screening Saves Lives
Lung cancer screening uses low-dose CT imaging to look for early disease in people who may be at increased risk but do not have symptoms. Detecting lung cancer earlier can expand treatment options and improve the likelihood of successful treatment.
- Early detection
- Low-dose CT
- UK and US criteria
- Lung nodules
- Emerging research
Screening is for people without symptoms
Screening aims to detect lung cancer before symptoms appear. A new or persistent cough, coughing up blood, chest pain or unexplained weight loss requires diagnostic assessment rather than waiting for screening.
Criteria continue to evolve
Current programmes focus mainly on age and smoking-related risk. Emerging research suggests that these criteria may miss some cancers, particularly in women, never-smokers and long-term former smokers.
Why early lung cancer detection matters
Lung cancer can develop without obvious symptoms during its early stages. Screening gives clinicians an opportunity to identify small abnormalities before the disease causes symptoms or spreads beyond the lung.
Lung cancer is the leading cause of cancer-related deaths worldwide. Early detection through lung cancer screening is a crucial step in reducing mortality rates and improving the prognosis for individuals at risk.
Here you will read about lung cancer screening, the procedures involved, and why it is essential to consult a lung specialist offering this service. By understanding the importance of lung cancer screening, if you are at high risk of lung cancer you can take greater control of your health.
Earlier diagnosis can provide access to a wider range of treatment options. Depending on the type, location and stage of the cancer, these may include surgery, stereotactic radiotherapy, conventional radiotherapy, systemic treatment or a combination of approaches.
Screening looks for early disease in people without symptoms. Diagnostic testing investigates symptoms or an abnormal finding that is already causing concern.
The importance of lung cancer screening
Lung cancer often presents without symptoms in its early stages, making it challenging to diagnose and treat promptly. When detected early, the chances of successful treatment are significantly higher, leading to better survival rates.
Lung cancer screening can identify the disease at an early stage, allowing for quicker intervention and improved outcomes.
Low-dose CT can identify small lung nodules that may not be visible on a standard chest X-ray. Most nodules are not cancer, but some require monitoring or further investigation.
Earlier diagnosis
Screening may detect a cancer before it causes symptoms or spreads to lymph nodes or other organs.
More treatment options
Small, localised cancers may be suitable for surgery or other treatments intended to eradicate the disease.
Lower lung cancer mortality
Evidence from targeted programmes shows that low-dose CT can reduce deaths from lung cancer in appropriately selected high-risk groups.
Why not use a standard chest X-ray?
Chest X-rays are useful for investigating many respiratory symptoms, but they are not sensitive enough to be used as the principal lung cancer screening test.
Low-dose CT produces detailed cross-sectional images and can identify smaller nodules that may be hidden on a chest X-ray.
Who should consider lung cancer screening?
Lung cancer screening is recommended for individuals at high risk of developing lung cancer. It is not routinely recommended for every adult because screening also has potential harms, including false-positive results, incidental findings and radiation exposure.
Current NHS screening group in England
People aged 55 to 74 who currently smoke or have smoked previously may be invited to participate in the NHS Lung Cancer Screening Programme as it reaches their local GP practice.
The initial appointment includes a lung health and individual risk assessment. People assessed as being at sufficiently high risk are offered a low-dose CT scan.
- Aged between 55 and 74
- Currently smoke or smoked previously
- Registered with a participating GP practice
- Invited by the local NHS screening service
- Complete an individual lung cancer risk assessment
- Considered suitable for low-dose CT screening
How is individual risk assessed?
Risk assessment considers more than whether a person has ever smoked. It may include age, smoking duration and intensity, previous cancer, family history, respiratory disease and other clinical factors.
Risk-prediction models such as PLCOm2012 may be used within screening pathways. The model considers factors including age, smoking history, body mass index, personal cancer history and family history of lung cancer.
What if you are outside the routine screening group?
Being younger than 55, older than 74 or never having smoked does not mean that lung cancer is impossible. Screening eligibility is based on population-level evidence and the balance of benefit and harm.
Anyone with concerning respiratory symptoms should seek medical assessment regardless of age or smoking history.
How do UK and US lung cancer screening criteria differ?
Lung cancer screening recommendations differ between countries and professional organisations. The main differences relate to age, smoking exposure, time since stopping smoking and the way an individual’s risk is calculated.
NHS programme
People aged 55 to 74 who currently smoke or previously smoked may be invited for a lung health check. An individual risk assessment is then used to determine who is offered low-dose CT.
USPSTF recommendation
Annual low-dose CT is recommended for adults aged 50 to 80 with at least 20 pack-years who currently smoke or stopped within the previous 15 years.
American Cancer Society
Annual low-dose CT is recommended for adults aged 50 to 80 with at least 20 pack-years who currently smoke or previously smoked, without a fixed 15-year stopping limit.
| Feature | NHS England | USPSTF | American Cancer Society |
|---|---|---|---|
| Age range | 55 to 74 | 50 to 80 | 50 to 80 |
| Smoking history | Current or previous smoking history, followed by formal individual risk assessment | At least 20 pack-years | At least 20 pack-years |
| Time since stopping | Considered within the broader individual risk assessment | Stopped no more than 15 years previously | No fixed stopping-time exclusion |
| Screening frequency | Determined by the organised NHS screening pathway | Annual | Annual |
| How entry is determined | Programme invitation followed by risk-model assessment | Age, pack-years and time since stopping | Age and pack-years |
Why do the criteria differ?
Different risk-selection strategies
The NHS pathway uses an organised invitation system followed by an individual risk calculation. The USPSTF uses simpler age-and-smoking thresholds.
Different evidence reviews
National organisations review clinical trials, modelling studies and population data using their own assessment processes.
Different healthcare systems
Screening programmes must fit the organisation, funding, capacity and follow-up pathways of each healthcare system.
Different benefit–harm thresholds
Policymakers may reach different conclusions about acceptable false-positive rates, radiation exposure, costs and numbers needed to screen.
Neither current UK nor US recommendations routinely offer population screening to all people who have never smoked, although lung cancer can occur without a personal smoking history.
Could current screening criteria be missing lung cancers?
Emerging evidence has raised concern that criteria centred mainly on smoking exposure may miss a substantial proportion of lung cancers occurring in women, never-smokers, some Asian populations and people who stopped smoking many years ago.
A 2025 Northwestern Medicine study published in JAMA Network Open analysed 997 consecutive patients diagnosed with lung cancer at one US academic health system between 2018 and 2023.
Patients studied
The retrospective cohort included people diagnosed with lung cancer within a single academic health system.
Met USPSTF criteria
Only around one-third of the patients would have been eligible under the 2021 USPSTF screening recommendation.
Modelled age-based coverage
The researchers estimated that screening adults aged 40 to 85 regardless of smoking history could include this proportion of cancers in their dataset.
Patients who did not meet the USPSTF criteria were enriched with women, people of Asian ethnicity, never-smokers and people who had stopped smoking more than 15 years previously.
The researchers also modelled an expanded strategy using ages 40 to 85, at least 10 pack-years and no time-since-quitting restriction. This would have included 62.1% of the cancers in the study cohort.
Why the findings are important
The study highlights a changing lung cancer population. Smoking remains the most important avoidable risk factor, but lung cancer also occurs in people with no or limited smoking exposure.
Second-hand smoke, radon, air pollution, occupational exposures, previous chest radiotherapy, family history and biological susceptibility may also influence risk.
What the study does not prove
The study does not establish that every adult aged 40 to 85 should immediately receive routine annual CT screening. It was a retrospective, single-health-system study of people who had already been diagnosed with lung cancer.
The wider detection and mortality benefits were modelled rather than measured in a prospective population screening trial. Broader screening could also increase false-positive findings, repeat scans, radiation exposure, overdiagnosis and invasive procedures for benign nodules.
Prospective studies are needed to determine whether broader or age-based screening reduces deaths while maintaining an acceptable balance of benefit, harm and cost.
What does this mean for female never-smokers?
The findings support further research into screening strategies that recognise risk beyond personal smoking history. They do not currently create a universal recommendation for routine CT screening of all female never-smokers.
A woman who has never smoked but has symptoms, a strong family history, previous chest radiotherapy or a significant environmental or occupational exposure should discuss her individual risk with an appropriate clinician.
Lung cancer screening procedure
Lung cancer screening typically involves a low-dose computed tomography scan. This non-invasive imaging test uses a low dose of radiation to capture detailed images of the lungs.
These images can reveal small nodules or growths that may indicate early-stage lung cancer.
- Enter a screening programme Eligible people enter an organised screening programme or undergo an appropriate specialist risk assessment.
- Lung health assessment Smoking history, general health, respiratory symptoms and other factors influencing lung cancer risk are reviewed.
- Risk calculation The information is used to estimate whether the person is likely to benefit from screening.
- Low-dose CT People assessed as being at higher risk undergo detailed imaging using less radiation than many standard diagnostic chest CT examinations.
- Specialist image review The images are examined for lung nodules, early cancer and other clinically important abnormalities.
- Results and follow-up The patient receives a result and, where needed, a plan for repeat scanning, further tests or specialist review.
Discuss risks and benefits
A clinician explains the procedure, possible outcomes and limitations so that the person can make an informed decision.
A quick, painless scan
You lie on a narrow table that passes through the CT scanner and may be asked to hold your breath briefly.
Expert image interpretation
A specialist analyses the images and recommends monitoring or additional investigation where appropriate.
What is a low-dose CT scan?
Low-dose CT uses X-rays and computer processing to create detailed lung images while limiting radiation exposure compared with many standard diagnostic CT examinations.
Screening scans are normally performed without an injection of contrast dye.
What happens after the scan?
Following the scan, a lung specialist or thoracic radiologist will analyse the images to identify abnormalities. If nodules or growths are detected, further tests may be necessary to determine whether they are cancerous.
Depending on the size and characteristics of the nodules, the specialist may recommend additional imaging, a biopsy or regular follow-up scans to monitor growth.
| Possible result | What it may mean | Typical next step |
|---|---|---|
| No concerning abnormality | No suspicious nodule or other finding requiring immediate investigation | Return to screening at the recommended interval where eligible |
| Small low-risk nodule | A small area is present but has features suggesting a low probability of cancer | Repeat low-dose CT after a defined interval |
| Indeterminate nodule | The finding cannot be confidently classified from one scan | Earlier repeat CT or specialist nodule assessment |
| Suspicious finding | The size, growth or appearance raises concern for possible lung cancer | Specialist assessment and possible PET-CT, bronchoscopy or biopsy |
| Other significant finding | The scan identifies another potentially important chest abnormality | Referral or follow-up according to clinical significance |
Why are repeat scans sometimes recommended?
Comparing scans over time helps determine whether a nodule is stable or growing. Stability can be reassuring, while measurable growth may increase concern.
A nodule does not automatically mean cancer
Lung nodules may be caused by previous infection, inflammation, scarring or benign growths. Their size, shape, density and growth rate help determine management.
Benefits and limitations of lung cancer screening
The primary benefit is the potential for early detection, which can improve treatment outcomes and survival rates. Screening also has limitations that should be understood before proceeding.
Potential benefits
- Detection before symptoms develop
- Diagnosis at an earlier stage
- Access to potentially curative treatment
- Reduced risk of dying from lung cancer
- Structured monitoring of certain nodules
- Access to smoking-cessation support
- More personalised healthcare planning
Potential limitations
- False-positive or indeterminate findings
- Anxiety while waiting for follow-up
- Additional tests for benign abnormalities
- Small cumulative radiation exposure
- Overdiagnosis of some slow-growing cancers
- Screening cannot detect every lung cancer
A normal screening scan reduces concern at that point in time but does not guarantee that lung cancer will never develop. New symptoms should still be investigated.
Screening should not delay investigation of symptoms
Screening is intended for people without symptoms. A person with potentially concerning symptoms needs diagnostic assessment, which may follow a different and faster pathway.
- A new cough that persists or worsens
- A change in a longstanding cough
- Coughing up blood
- Unexplained breathlessness
- Persistent chest or shoulder pain
- Unexplained weight loss
- Loss of appetite
- Unusual persistent fatigue
- Repeated chest infections
- Persistent hoarseness
Do not wait for an invitation if you have symptoms
Contact a healthcare professional if you develop symptoms that could indicate lung cancer or another significant respiratory condition.
Getting your lung screening health check
Finding a lung specialist is essential when considering private lung cancer screening or when an NHS screening scan identifies an abnormality.
Relevant experience
Look for a respiratory specialist with experience diagnosing lung cancer and managing smoking-related lung disease.
Multidisciplinary access
The specialist should have access to thoracic radiologists, interventional bronchoscopists, oncologists and thoracic surgeons.
Whole-person assessment
Good care considers COPD, emphysema, cardiovascular health, previous cancer and other factors affecting treatment choices.
Clear communication
The specialist should listen, answer questions and explain screening results and follow-up plans clearly.
- Specialist thoracic radiology review
- Reliable systems for follow-up imaging
- Access to bronchoscopy and biopsy
- Access to a lung cancer multidisciplinary team
- Modern low-dose CT technology
- Clear explanation of benefits and limitations
- Management of smoking-related lung disease
- Prompt communication of results
Taking control of your lung health
Participating in screening when invited is one way of taking an active role in lung health. Smoking cessation remains one of the most important steps for reducing future lung cancer risk.
It is never too late to stop smoking
Stopping smoking reduces future risk even after many years of tobacco exposure. It also benefits heart health, circulation, COPD risk and recovery from treatment.
Attend recommended follow-up
If a repeat scan is recommended, attending at the advised interval is important. Change over time may be more informative than appearance on one scan.
Keep your GP smoking record accurate
Screening invitations may rely partly on information held by the GP practice. Make sure your current or previous smoking history is recorded accurately.
Conclusion
Lung cancer screening is a critical tool in the early detection and treatment of lung cancer. By identifying lung cancer at an early stage, individuals at high risk can receive care sooner, increasing their chances of successful treatment and survival.
In England, the NHS programme is being expanded for people aged 55 to 74 who currently smoke or have smoked previously. An individual risk assessment determines who is offered low-dose CT.
US recommendations use different age and smoking thresholds. Emerging research suggests that current smoking-centred criteria may miss cancers in women, never-smokers and some other groups, but broader universal screening has not yet been established as standard care.
Consult a lung specialist who can evaluate lung cancer risk, assess respiratory symptoms and manage smoking-related lung disease. This comprehensive approach allows screening and follow-up to be tailored safely to the individual.
Frequently asked questions
Who is eligible for NHS lung cancer screening?
The NHS programme in England is being expanded for people aged 55 to 74 who currently smoke or have smoked previously. Those invited undergo a risk assessment, and people at higher risk are offered low-dose CT.
How do US screening criteria differ from UK criteria?
The USPSTF recommends annual CT for adults aged 50 to 80 with at least 20 pack-years who currently smoke or quit within 15 years. The NHS pathway begins with people aged 55 to 74 who have smoked and then applies an individual risk assessment.
Does the American Cancer Society use a 15-year quitting limit?
No. Its recommendation uses ages 50 to 80 and at least 20 pack-years but does not exclude people solely because they stopped smoking more than 15 years ago.
Should female never-smokers have routine CT screening?
Routine population screening of all female never-smokers is not currently recommended. Emerging research supports better risk models and prospective trials, but the benefits and harms of broad screening still need to be established.
What did the Northwestern study show?
In a retrospective cohort of 997 patients with lung cancer, only 35.1% met current USPSTF criteria. Patients outside the criteria included disproportionate numbers of women, never-smokers, Asian patients and long-term former smokers.
Can I book NHS lung cancer screening myself?
The programme generally operates by invitation as it reaches participating GP practices and local areas. People with symptoms should seek diagnostic care instead.
Is a low-dose CT scan painful?
No. It is painless and usually takes only a few minutes. You may be asked to hold your breath briefly.
Does lung cancer screening use contrast dye?
Screening low-dose CT is normally performed without intravenous contrast.
Does finding a lung nodule mean I have cancer?
No. Most lung nodules are not cancer. Size, appearance and behaviour over time guide whether monitoring or investigation is required.
Should I wait for screening if I am coughing up blood?
No. Coughing up blood requires medical assessment. Screening is designed for people without symptoms.
References and official information
- NHS. Lung cancer screening. View NHS information
- UK National Screening Committee. Lung cancer screening recommendation. View recommendation
- US Preventive Services Task Force. Lung Cancer: Screening. View USPSTF recommendation
- American Cancer Society. Lung Cancer Screening Guidelines. View ACS guidance
- Yang HC, et al. Age-Based Screening for Lung Cancer Surveillance in the US. JAMA Network Open. 2025. View publication
<style data-wp-block-html="css">
.lcs-blog-cta,
.lcs-blog-cta * {
box-sizing: border-box;
}
.lcs-blog-cta {
--lcs-cta-navy: #082b55;
--lcs-cta-navy-dark: #061f3d;
--lcs-cta-blue: #17689e;
--lcs-cta-orange: #e86f2d;
--lcs-cta-orange-dark: #c9571d;
--lcs-cta-text: #1f3344;
--lcs-cta-muted: #41596b;
--lcs-cta-border: #d7e4ec;
--lcs-cta-white: #ffffff;
--lcs-cta-light: #f4f8fb;
width: 100%;
margin: clamp(60px, 8vw, 100px) 0 0;
padding: 0 clamp(18px, 5vw, 64px);
color: var(--lcs-cta-text);
font-family:
Inter,
-apple-system,
BlinkMacSystemFont,
"Segoe UI",
Roboto,
Helvetica,
Arial,
sans-serif;
}
.lcs-blog-cta__inner {
width: 100%;
max-width: 1240px;
margin: 0 auto;
}
.lcs-blog-cta__panel {
position: relative;
isolation: isolate;
display: grid;
grid-template-columns: minmax(0, 1fr) minmax(210px, 300px);
gap: clamp(30px, 5vw, 72px);
align-items: center;
padding: clamp(34px, 6vw, 68px);
overflow: hidden;
border-radius: 26px;
background:
radial-gradient(
circle at 90% 12%,
rgba(49, 148, 202, 0.28),
rgba(49, 148, 202, 0) 36%
),
radial-gradient(
circle at 4% 96%,
rgba(232, 111, 45, 0.18),
rgba(232, 111, 45, 0) 32%
),
linear-gradient(
135deg,
var(--lcs-cta-navy-dark),
var(--lcs-cta-navy) 62%,
#0d4775
);
box-shadow: 0 24px 64px rgba(8, 43, 85, 0.16);
}
.lcs-blog-cta__panel::before {
position: absolute;
z-index: -1;
top: -180px;
right: -100px;
width: 400px;
height: 400px;
border: 1px solid rgba(255, 255, 255, 0.11);
border-radius: 50%;
content: "";
}
.lcs-blog-cta__content {
position: relative;
z-index: 2;
min-width: 0;
}
.lcs-blog-cta__eyebrow {
display: inline-flex;
align-items: center;
gap: 10px;
margin: 0 0 18px;
color: #dceff9;
font-size: 0.8rem;
font-weight: 700;
letter-spacing: 0.12em;
line-height: 1.4;
text-transform: uppercase;
}
.lcs-blog-cta__eyebrow::before {
flex: 0 0 auto;
width: 34px;
height: 3px;
border-radius: 999px;
background: var(--lcs-cta-orange);
content: "";
}
.lcs-blog-cta__content h2 {
max-width: 720px;
margin: 0;
color: var(--lcs-cta-white);
font-size: clamp(2rem, 4vw, 3.5rem);
font-weight: 750;
letter-spacing: -0.045em;
line-height: 1.08;
text-wrap: balance;
}
.lcs-blog-cta__text {
max-width: 650px;
margin: 22px 0 0;
color: #eef7fb;
font-size: clamp(1rem, 1.5vw, 1.18rem);
line-height: 1.7;
}
.lcs-blog-cta__actions {
display: flex;
flex-wrap: wrap;
gap: 12px;
margin-top: 30px;
}
.lcs-blog-cta__button {
display: inline-flex;
min-height: 50px;
align-items: center;
justify-content: center;
padding: 13px 22px;
border: 2px solid transparent;
border-radius: 999px;
font-size: 0.96rem;
font-weight: 700;
line-height: 1.3;
text-align: center;
text-decoration: none;
transition:
background-color 180ms ease,
border-color 180ms ease,
color 180ms ease,
transform 180ms ease;
}
.lcs-blog-cta__button:hover {
transform: translateY(-2px);
}
.lcs-blog-cta__button:focus-visible {
outline: 3px solid rgba(255, 255, 255, 0.7);
outline-offset: 4px;
}
.lcs-blog-cta__button--primary {
background: var(--lcs-cta-orange);
color: var(--lcs-cta-white);
box-shadow: 0 12px 30px rgba(197, 83, 30, 0.28);
}
.lcs-blog-cta__button--primary:hover,
.lcs-blog-cta__button--primary:focus-visible {
background: var(--lcs-cta-orange-dark);
color: var(--lcs-cta-white);
}
.lcs-blog-cta__button--secondary {
border-color: rgba(255, 255, 255, 0.45);
background: rgba(255, 255, 255, 0.08);
color: var(--lcs-cta-white);
}
.lcs-blog-cta__button--secondary:hover,
.lcs-blog-cta__button--secondary:focus-visible {
border-color: var(--lcs-cta-white);
background: var(--lcs-cta-white);
color: var(--lcs-cta-navy);
}
.lcs-blog-cta__visual {
display: grid;
width: min(100%, 280px);
aspect-ratio: 1;
place-items: center;
justify-self: end;
color: rgba(255, 255, 255, 0.85);
}
.lcs-blog-cta__visual svg {
display: block;
width: 100%;
height: auto;
}
.lcs-blog-cta__disclaimer {
margin-top: 20px;
padding: clamp(24px, 4vw, 34px);
border: 1px solid var(--lcs-cta-border);
border-radius: 18px;
background: var(--lcs-cta-light);
}
.lcs-blog-cta__disclaimer h2 {
margin: 0 0 12px;
color: var(--lcs-cta-navy);
font-size: 1.08rem;
font-weight: 750;
letter-spacing: -0.015em;
line-height: 1.4;
}
.lcs-blog-cta__disclaimer p {
max-width: 100ch;
margin: 0 0 10px;
color: var(--lcs-cta-muted);
font-size: 0.9rem;
line-height: 1.68;
}
.lcs-blog-cta__disclaimer p:last-child {
margin-bottom: 0;
}
@media (max-width: 820px) {
.lcs-blog-cta__panel {
grid-template-columns: 1fr;
}
.lcs-blog-cta__visual {
position: absolute;
right: -34px;
bottom: -38px;
width: 220px;
opacity: 0.16;
}
.lcs-blog-cta__content {
max-width: 680px;
}
}
@media (max-width: 580px) {
.lcs-blog-cta {
padding-right: 16px;
padding-left: 16px;
}
.lcs-blog-cta__panel {
padding: 32px 24px;
border-radius: 20px;
}
.lcs-blog-cta__content h2 {
font-size: clamp(1.85rem, 9vw, 2.5rem);
}
.lcs-blog-cta__actions {
display: grid;
grid-template-columns: 1fr;
}
.lcs-blog-cta__button {
width: 100%;
}
.lcs-blog-cta__visual {
right: -58px;
bottom: -50px;
width: 200px;
}
.lcs-blog-cta__disclaimer {
padding: 22px 20px;
border-radius: 15px;
}
}
@media (prefers-reduced-motion: reduce) {
.lcs-blog-cta__button {
transition: none;
}
.lcs-blog-cta__button:hover {
transform: none;
}
}
</style>
<style data-wp-block-html="css">
.lcs-blog-cta,
.lcs-blog-cta * {
box-sizing: border-box;
}
.lcs-blog-cta {
--lcs-cta-navy: #082b55;
--lcs-cta-navy-dark: #061f3d;
--lcs-cta-blue: #17689e;
--lcs-cta-orange: #e86f2d;
--lcs-cta-orange-dark: #c9571d;
--lcs-cta-text: #1f3344;
--lcs-cta-muted: #41596b;
--lcs-cta-border: #d7e4ec;
--lcs-cta-white: #ffffff;
--lcs-cta-light: #f4f8fb;
width: 100%;
margin: clamp(60px, 8vw, 100px) 0 0;
padding: 0 clamp(18px, 5vw, 64px);
color: var(--lcs-cta-text);
font-family:
Inter,
-apple-system,
BlinkMacSystemFont,
"Segoe UI",
Roboto,
Helvetica,
Arial,
sans-serif;
}
.lcs-blog-cta__inner {
width: 100%;
max-width: 1240px;
margin: 0 auto;
}
.lcs-blog-cta__panel {
position: relative;
isolation: isolate;
display: grid;
grid-template-columns: minmax(0, 1fr) minmax(210px, 300px);
gap: clamp(30px, 5vw, 72px);
align-items: center;
padding: clamp(34px, 6vw, 68px);
overflow: hidden;
border-radius: 26px;
background:
radial-gradient(
circle at 90% 12%,
rgba(49, 148, 202, 0.28),
rgba(49, 148, 202, 0) 36%
),
radial-gradient(
circle at 4% 96%,
rgba(232, 111, 45, 0.18),
rgba(232, 111, 45, 0) 32%
),
linear-gradient(
135deg,
var(--lcs-cta-navy-dark),
var(--lcs-cta-navy) 62%,
#0d4775
);
box-shadow: 0 24px 64px rgba(8, 43, 85, 0.16);
}
.lcs-blog-cta__panel::before {
position: absolute;
z-index: -1;
top: -180px;
right: -100px;
width: 400px;
height: 400px;
border: 1px solid rgba(255, 255, 255, 0.11);
border-radius: 50%;
content: "";
}
.lcs-blog-cta__content {
position: relative;
z-index: 2;
min-width: 0;
}
.lcs-blog-cta__eyebrow {
display: inline-flex;
align-items: center;
gap: 10px;
margin: 0 0 18px;
color: #dceff9;
font-size: 0.8rem;
font-weight: 700;
letter-spacing: 0.12em;
line-height: 1.4;
text-transform: uppercase;
}
.lcs-blog-cta__eyebrow::before {
flex: 0 0 auto;
width: 34px;
height: 3px;
border-radius: 999px;
background: var(--lcs-cta-orange);
content: "";
}
.lcs-blog-cta__content h2 {
max-width: 720px;
margin: 0;
color: var(--lcs-cta-white);
font-size: clamp(2rem, 4vw, 3.5rem);
font-weight: 750;
letter-spacing: -0.045em;
line-height: 1.08;
text-wrap: balance;
}
.lcs-blog-cta__text {
max-width: 650px;
margin: 22px 0 0;
color: #eef7fb;
font-size: clamp(1rem, 1.5vw, 1.18rem);
line-height: 1.7;
}
.lcs-blog-cta__actions {
display: flex;
flex-wrap: wrap;
gap: 12px;
margin-top: 30px;
}
.lcs-blog-cta__button {
display: inline-flex;
min-height: 50px;
align-items: center;
justify-content: center;
padding: 13px 22px;
border: 2px solid transparent;
border-radius: 999px;
font-size: 0.96rem;
font-weight: 700;
line-height: 1.3;
text-align: center;
text-decoration: none;
transition:
background-color 180ms ease,
border-color 180ms ease,
color 180ms ease,
transform 180ms ease;
}
.lcs-blog-cta__button:hover {
transform: translateY(-2px);
}
.lcs-blog-cta__button:focus-visible {
outline: 3px solid rgba(255, 255, 255, 0.7);
outline-offset: 4px;
}
.lcs-blog-cta__button--primary {
background: var(--lcs-cta-orange);
color: var(--lcs-cta-white);
box-shadow: 0 12px 30px rgba(197, 83, 30, 0.28);
}
.lcs-blog-cta__button--primary:hover,
.lcs-blog-cta__button--primary:focus-visible {
background: var(--lcs-cta-orange-dark);
color: var(--lcs-cta-white);
}
.lcs-blog-cta__button--secondary {
border-color: rgba(255, 255, 255, 0.45);
background: rgba(255, 255, 255, 0.08);
color: var(--lcs-cta-white);
}
.lcs-blog-cta__button--secondary:hover,
.lcs-blog-cta__button--secondary:focus-visible {
border-color: var(--lcs-cta-white);
background: var(--lcs-cta-white);
color: var(--lcs-cta-navy);
}
.lcs-blog-cta__visual {
display: grid;
width: min(100%, 280px);
aspect-ratio: 1;
place-items: center;
justify-self: end;
color: rgba(255, 255, 255, 0.85);
}
.lcs-blog-cta__visual svg {
display: block;
width: 100%;
height: auto;
}
.lcs-blog-cta__disclaimer {
margin-top: 20px;
padding: clamp(24px, 4vw, 34px);
border: 1px solid var(--lcs-cta-border);
border-radius: 18px;
background: var(--lcs-cta-light);
}
.lcs-blog-cta__disclaimer h2 {
margin: 0 0 12px;
color: var(--lcs-cta-navy);
font-size: 1.08rem;
font-weight: 750;
letter-spacing: -0.015em;
line-height: 1.4;
}
.lcs-blog-cta__disclaimer p {
max-width: 100ch;
margin: 0 0 10px;
color: var(--lcs-cta-muted);
font-size: 0.9rem;
line-height: 1.68;
}
.lcs-blog-cta__disclaimer p:last-child {
margin-bottom: 0;
}
@media (max-width: 820px) {
.lcs-blog-cta__panel {
grid-template-columns: 1fr;
}
.lcs-blog-cta__visual {
position: absolute;
right: -34px;
bottom: -38px;
width: 220px;
opacity: 0.16;
}
.lcs-blog-cta__content {
max-width: 680px;
}
}
@media (max-width: 580px) {
.lcs-blog-cta {
padding-right: 16px;
padding-left: 16px;
}
.lcs-blog-cta__panel {
padding: 32px 24px;
border-radius: 20px;
}
.lcs-blog-cta__content h2 {
font-size: clamp(1.85rem, 9vw, 2.5rem);
}
.lcs-blog-cta__actions {
display: grid;
grid-template-columns: 1fr;
}
.lcs-blog-cta__button {
width: 100%;
}
.lcs-blog-cta__visual {
right: -58px;
bottom: -50px;
width: 200px;
}
.lcs-blog-cta__disclaimer {
padding: 22px 20px;
border-radius: 15px;
}
}
@media (prefers-reduced-motion: reduce) {
.lcs-blog-cta__button {
transition: none;
}
.lcs-blog-cta__button:hover {
transform: none;
}
}
</style>
<section class="lcs-blog-cta" aria-labelledby="lcs-blog-cta-title">
<div class="lcs-blog-cta__inner">
<div class="lcs-blog-cta__panel">
<div class="lcs-blog-cta__content">
<p class="lcs-blog-cta__eyebrow">Get in touch</p>
<h2 id="lcs-blog-cta-title">
Schedule a Visit with Dr José
</h2>
<p class="lcs-blog-cta__text">
Arrange a consultation for an individual assessment of your
diagnosis, symptoms and treatment options.
</p>
<div class="lcs-blog-cta__actions">
<a class="lcs-blog-cta__button lcs-blog-cta__button--primary" href="https://londonchestspecialist.co.uk/online-booking-2/">
Book a consultation
</a>
<a class="lcs-blog-cta__button lcs-blog-cta__button--secondary" href="https://londonchestspecialist.co.uk/contact/">
Contact us
</a>
</div>
</div>
<div class="lcs-blog-cta__visual" aria-hidden="true">
<svg viewBox="0 0 260 260" role="presentation" focusable="false">
<circle cx="130" cy="130" r="104" fill="none" stroke="currentColor" stroke-width="2" opacity="0.16"></circle>
<circle cx="130" cy="130" r="78" fill="none" stroke="currentColor" stroke-width="2" opacity="0.22"></circle>
<path d="M130 64v48" fill="none" stroke="currentColor" stroke-width="7" stroke-linecap="round"></path>
<path d="M130 110c-12 5-22 16-28 29" fill="none" stroke="currentColor" stroke-width="6" stroke-linecap="round"></path>
<path d="M130 110c12 5 22 16 28 29" fill="none" stroke="currentColor" stroke-width="6" stroke-linecap="round"></path>
<path d="M118 101c-28 8-48 36-48 68 0 20 9 31 24 31 18 0 30-19 30-45v-43" fill="none" stroke="currentColor" stroke-width="7" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M142 101c28 8 48 36 48 68 0 20-9 31-24 31-18 0-30-19-30-45v-43" fill="none" stroke="currentColor" stroke-width="7" stroke-linecap="round" stroke-linejoin="round"></path>
</svg>
</div>
</div>
<div class="lcs-blog-cta__disclaimer">
<h2>Medical information disclaimer</h2>
<p>
The information provided in this article is for informational purposes
only and is not a substitute for professional medical advice,
diagnosis or treatment. It is not an advertisement for medical
products.
</p>
<p>
Always seek the advice of your healthcare provider with any questions
you may have regarding a medical condition or treatment. Your
healthcare professional can assess your individual circumstances. All
clinical decisions should follow an individual assessment and shared
decision-making.
<p class="lcs-disclaimer__review">
Content reviewed by Dr Ricardo José, Consultant Respiratory Physician at London Chest Specialist.
</p>
</p>
</div>
</div>
</section>